Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: paclitaxel

« Back to Dashboard

Paclitaxel is the generic ingredient in three branded drugs marketed by Abraxis Bioscience, Accord Hlthcare, Actavis Totowa, Ebewe Pharma, Eurohlth Intl, Fresenius Kabi Oncol, Hospira, Mylan, Onco Therapies Ltd, Pliva Lachema, Teva Pharms, Teva Pharms Usa, and Hq Spclt Pharma, and is included in fourteen NDAs. There are nine patents protecting this compound. Additional information is available in the individual branded drug profile pages.

There are sixty-three drug master file entries for paclitaxel. Two suppliers are listed for this compound.

Summary for Generic Name: paclitaxel

Tradenames:3
Patents:9
Applicants:13
NDAs:14
Drug Master File Entries: see list63
Suppliers: see list2

Pharmacology for Ingredient: paclitaxel

Drug ClassMicrotubule Inhibitor
Physiological EffectMicrotubule Inhibition

Clinical Trials for: paclitaxel

Hepatic Arterial Infusion (HAI) of Abraxane
Status: Active, not recruiting Condition: Liver Cancer; Advanced Cancers; Solid Tumors

Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer
Status: Completed Condition: Breast Cancer

Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma
Status: Recruiting Condition: Resectable Pancreatic Adenocarcinoma

Phase I & II Trial of Intravesicular Abraxane for Treatment-refractory Bladder Cancer
Status: Recruiting Condition: Bladder Cancer

Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
Status: Completed Condition: Metastatic Breast Cancer

A Phase I Trial of the Combination of AZD2014 and Weekly Paclitaxel.
Status: Recruiting Condition: Advanced Cancer

Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast Cancer
Status: Terminated Condition: Breast Neoplasms; Neoplasm Metastasis

Pharmacokinetic and Safety Study of Nab®-Paclitaxel (ABI-007) Plus Gemcitabine in Subjects With Advanced Pancreatic Cancer Who Have Cholestatic Hyperbilirubenemia
Status: Not yet recruiting Condition: Pancreatic Neoplasms; Cholestasis

Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma
Status: Recruiting Condition: Melanoma

HAI Abraxane With Gemcitabine and Bevacizumab
Status: Completed Condition: Advanced Cancers

Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer
Status: Recruiting Condition: Squamous Cell Carcinoma, Non-Small-Cell Lung

BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors
Status: Recruiting Condition: Solid Tumors

A Randomized Study of Intraperitoneal tgDCC-E1 and Intravenous Paclitaxel in Women With Platinum-Resistant Ovarian Cancer
Status: Withdrawn Condition: Ovarian Cancer

A Study of Ramucirumab (IMC-1121B) and Paclitaxel in Participants With Solid Tumors
Status: Active, not recruiting Condition: Malignant Solid Tumor

Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple Myeloma
Status: Recruiting Condition: Relapsed or Refractory Multiple Myeloma

Assessment Of Stromal Response To Nab-Paclitaxel In Combination With Gemcitabine In Pancreatic Cancer
Status: Completed Condition: Pancreatic Cancer

Safety and Efficacy Study of Abraxane Plus Gemcitabine in Chinese Patients With Metastatic Pancreatic Cancer
Status: Active, not recruiting Condition: Pancreatic Neoplasms

Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 and Nab®-Paclitaxel Monotherapy as Second Line Treatment for Advanced Nonsquamous Non-small Cell Lung Cancer
Status: Not yet recruiting Condition: Carcinoma, Non-Small-Cell Lung

Intraperitoneal tgDCC-E1 and Intravenous Paclitaxel in Women With Platinum-Resistant Ovarian Cancer
Status: Terminated Condition: Ovarian Cancer

Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Status: Active, not recruiting Condition: Adenocarcinoma of the Esophagus; Adenocarcinoma of the Gastroesophageal Junction; Recurrent Esophageal Cancer; Squamous Cell Carcinoma of the Esophagus; Stage IV Esophageal Cancer

Cisplatin vs Paclitaxel for Triple Neg BRCA
Status: Recruiting Condition: Triple Negative Breast Cancer

Phase II Trial Comparing ABI-007 (Abraxane®, Nab®-Paclitaxel) to Taxotere in First Line Therapy of Patients With Stage IV Breast Cancer
Status: Completed Condition: Metastatic Breast Cancer

Schedules of Nab-Paclitaxel in Metastatic Breast Cancer
Status: Recruiting Condition: Metastatic Breast Cancer.

A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
Status: Completed Condition: Malignant Melanoma

PH I SRC Kinase, Dasatinib Combo Paclitaxel & Carboplatin in Pts w Ovarian, Peritoneal, & Tubal Cancer
Status: Completed Condition: Ovarian Cancer; Peritoneal Cancer; Fallopian Tube Cancer

Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer)
Status: Completed Condition: Brenner Tumor; Fallopian Tube Cancer; Ovarian Carcinosarcoma; Ovarian Clear Cell Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mixed Epithelial Carcinoma; Ovarian Mucinous Cystadenocarcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Undifferentiated Adenocarcinoma; Primary Peritoneal Cavity Cancer; Stage II Ovarian Epithelial Cancer; Stage III Ovarian Epithelial Cancer; Stage IV Ovarian Epithelial Cancer

ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer
Status: Completed Condition: Metastatic Breast Cancer

Efficacy of ABI-007 Plus Gemcitabine or sLV5FU2 as First-line Therapy in Patients With Metastatic Pancreatic Cancer
Status: Active, not recruiting Condition: Metastatic Pancreatic Cancer

Abraxane in CIMP-High Colorectal and Small Bowel Adenocarcinomas
Status: Recruiting Condition: Colorectal Cancer; Cancer of Gastrointestinal Tract

A Phase I Trial of Abraxane, Cisplatin and 5-Fluorouracil Along With Chemoradiotherapy in Advanced Head and Neck Cancer
Status: Active, not recruiting Condition: Head and Neck Cancer

Trial of Combination ABI-007, Carboplatin, and Gemcitabine for First Line Treatment of Advanced Urothelial Cancer
Status: Completed Condition: Urothelial Cancer; Bladder Cancer

Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma
Status: Active, not recruiting Condition: Uterine Cancer

Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer
Status: Not yet recruiting Condition: Breast Neoplasms; Pancreatic Neoplasms

Dasatinib In Combination With Weekly Paclitaxel For Patients With Metastatic Breast Carcinoma CA 180 194
Status: Active, not recruiting Condition: Breast Cancer

Dose Escalation and Pharmacokinetic Study of Paclitaxel Liposome Injection in Treating Patients With Advanced Solid Tumor After Failure From Conventional Treatments
Status: Recruiting Condition: Solid Tumors

Bevacizumab and Abraxane as Second-line Therapy in Triple Negative Metastatic Breast Cancer
Status: Completed Condition: Breast Cancer

Study of Vemurafenib, Carboplatin, and Paclitaxel
Status: Recruiting Condition: Advanced Cancers

Study of Concurrent Paclitaxel and Radiation: Correlation of Tumor Profiles With Pathologic Response
Status: Recruiting Condition: Breast Cancer

Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer
Status: Completed Condition: Breast Cancer

Bioequivalence Study of IG-001 Versus Nab-paclitaxel in Metastatic or Locally Recurrent Breast Cancer
Status: Recruiting Condition: Metastatic Breast Cancer; Locally Recurrent Breast Cancer

Hepatic Arterial Infusion of Nab-Paclitaxel in Patients With Metastatic Melanoma in the Liver
Status: Completed Condition: Melanoma; Liver Metastasis

Phase 1b/2 Study of U3-1287 in Combination With Trastuzumab Plus Paclitaxel in Newly Diagnosed Metastatic Breast Cancer (MBC)
Status: Active, not recruiting Condition: Metastatic Breast Cancer

Study Of Abraxane® And Carboplatin As First-Line Treatment For Triple Negative Metastatic Breast Cancer
Status: Terminated Condition: Metastatic Breast Cancer

Phase I/II AZD8931/Paclitaxel in Treatment of Advanced Solid Tumours (Phase I) and Advanced Breast Cancer (Phase II)
Status: Active, not recruiting Condition: Neoplasms; Breast Neoplasms; Breast Cancer

Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
Status: Completed Condition: Brenner Tumor; Fallopian Tube Cancer; Ovarian Clear Cell Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mixed Epithelial Carcinoma; Ovarian Mucinous Cystadenocarcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Undifferentiated Adenocarcinoma; Primary Peritoneal Cavity Cancer; Stage II Ovarian Epithelial Cancer; Stage III Ovarian Epithelial Cancer; Stage IV Ovarian Epithelial Cancer

Phase I Study of the Combination of Satraplatin and Abraxane in Advanced Cancers
Status: Completed Condition: Advanced Cancers

Cisplatin, Temozolomide, Abraxane, With Interleukin-2 and Interferon for Metastatic Melanoma
Status: Completed Condition: Melanoma

Nab-paclitaxel, Gemcitabine, and Bevacizumab in Advanced Malignancies
Status: Recruiting Condition: Advanced Cancer

Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer
Status: Not yet recruiting Condition: Breast Cancer; Breast Carcinoma; Breast Tumors; Malignant Neoplasm of Breast

A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer
Status: Terminated Condition: Stage IV (Metastatic) Breast Cancer

Lenalidomide and Paclitaxel in Prostate Cancer
Status: Active, not recruiting Condition: Prostate Cancer

A Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Non-Small Cell Lung Cancer
Status: Completed Condition: Non-Small Cell Lung Cancer

PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Untreated Pancreatic Cancer
Status: Recruiting Condition: Metastatic Pancreatic Cancer

Study Comparing Nanoparticle-based Paclitaxel With Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Patients With Early Breast Cancer (GeparSepto)
Status: Active, not recruiting Condition: Tubular Breast Cancer Stage II; Mucinous Breast Cancer Stage II; Breast Cancer Female NOS; Invasive Ductal Breast Cancer; Tubular Breast Cancer Stage III; HER-2 Positive Breast Cancer; Inflammatory Breast Cancer Stage IV; Inflammatory Breast Cancer

Lapatinib in Combination With Weekly Paclitaxel in Patients With ErbB2 Amplified Advanced Gastric Cancer
Status: Completed Condition: Neoplasms, Gastrointestinal Tract

Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer
Status: Active, not recruiting Condition: Chemotherapeutic Agent Toxicity; Neuropathy; Neurotoxicity Syndrome; Pain; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer

Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer
Status: Active, not recruiting Condition: Breast Cancer; Triple Negative Breast Cancer; Stage IV Breast Cancer; Metastatic Breast Cancer

Phase 2 Nab® -Paclitaxel (Abraxane®) Plus Gemcitabine in Subjects With Locally Advanced Pancreatic Cancer (LAPC)
Status: Not yet recruiting Condition: Pancreatic Neoplasms

A Study of BBI608 in Combination With Gemcitabine and Nab-Paclitaxel in Adult Patients With Metastatic Pancreatic Adenocarcinoma
Status: Recruiting Condition: Metastatic Pancreatic Adenocarcinoma

Phase II Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer
Status: Recruiting Condition: Borderline Resectable Pancreatic Cancer

Study of Gemcitabine and Abraxane for Pancreas Cancer
Status: Recruiting Condition: Pancreatic Cancer

Phase I/II Study of Abraxane in Recurrent and Refractory Lymphoma
Status: Recruiting Condition: Lymphoma, Non-Hodgkin; Hodgkin Disease

Trial to Evaluate Paclitaxel Plus RAD001 in Urothelial Carcinoma
Status: Terminated Condition: Bladder Cancer

Phase IB/II Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer
Status: Not yet recruiting Condition: Recurrent Ovarian Cancer; Platinum Resistant

Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
Status: Active, not recruiting Condition: Squamous Cell Cancer; Head and Neck Cancer

Investigating Safety, Tolerability and Efficacy of AZD5363 When Combined With Paclitaxel in Breast Cancer Patients
Status: Recruiting Condition: Advanced or Metastatic Breast Cancer,; ER+ve Advanced or Metastatic Breast Cancer.

A Study of Gemcitabine and Demcizumab (OMP-21M18) With or Without Abraxane® as 1st-line Treatment in Subjects With Locally Advanced or Metastatic Pancreatic Cancer
Status: Recruiting Condition: Pancreatic Cancer

A Phase 3 Study to Compare Efficacy and Safety of DHP107 Versus Taxol® in Patients With Metastatic or Recurrent Gastric Cancer After Failure of First-line Chemotherapy
Status: Recruiting Condition: Stage IV Gastric Cancer

Paclitaxel Administered by HAI to Patients With Advanced Cancer and Dominant Liver Involvement
Status: Completed Condition: Advanced Cancer

Intraperitoneal Paclitaxel and Carboplatin With IV Avastin Therapy in Patients With Carcinomas of Mullerian Origin
Status: Active, not recruiting Condition: Ovarian Cancer; Peritoneal Cancer; Fallopian Tube Cancer

Study of Abraxane and Carboplatin to Treat Small Cell Lung Cancer
Status: Active, not recruiting Condition: Small Cell Lung Cancer

Phase I/Ib Study of Paclitaxel in Combination With VS-6063 in Patients With Advanced Ovarian Cancer
Status: Active, not recruiting Condition: Ovarian Cancer

Dose Dense Abraxane in Adjuvant Chemotherapy for Breast Cancer
Status: Completed Condition: Breast Cancer

Paclitaxel-Carboplatin-Bevacizumab +/- Nitroglycerin in Metastatic Non-Squamous-Non-Small Cell Lung Cancer
Status: Recruiting Condition: Non Small Cell Lung Cancer

Prevention of Paclitaxel Neuropathy With Cryotherapy
Status: Recruiting Condition: Breast Cancer

F16IL2 Plus Paclitaxel in Metastatic Merkel Cell Carcinoma
Status: Recruiting Condition: Merkel Cell Carcinoma

A Combination of Abraxane and Cisplatin in Metastatic Breast Cancer
Status: Completed Condition: Metastatic Breast Cancer

Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies
Status: Active, not recruiting Condition: Advanced Cancer

Study of Afuresertib Combined With Paclitaxel in Gastric Cancer
Status: Recruiting Condition: Cancer

Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)
Status: Recruiting Condition: Breast Tumor; Breast Cancer; Cancer of the Breast; Estrogen Receptor- Negative Breast Cancer; HER2- Negative Breast Cancer; Progesterone Receptor- Negative Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer; Triple-negative Breast Cancer; Triple-negative Metastatic Breast Cancer; Metastatic Breast Cancer

To Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors
Status: Recruiting Condition: Neuroblastoma;; Rhabdomyosarcoma;; Ewing's Sarcoma;; Ewing's Tumor;; Sarcoma, Ewing's;; Sarcomas, Epitheliod;; Sarcoma, Soft Tissue;; Sarcoma, Spindle Cell;; Melanoma;; Malignant Melanoma;; Clinical Oncology;; Oncology, Medical;; Pediatrics, Osteosarcoma;; Osteogenic Sarcoma;; Osteosarcoma Tumor;; Sarcoma, Osteogenic;; Tumors;; Cancer;; Neoplasia;; Neoplasm;; Histiocytoma;; Fibrosarcoma;; Dermatofibrosarcoma

Carboplatin and Paclitaxel Combined With Cetuximab and/or IMC-A12 in Patients With Advanced Non-Small Cell Lung Cancer
Status: Completed Condition: Recurrent Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer

Paclitaxel, Bevacizumab and Pemetrexed in Patients With Untreated, Advanced Non-Small Cell Lung Cancer Using Web-Based Data Collection, Patient Self-Reporting of Adverse Effects and Automated Response Assessment
Status: Completed Condition: Lung Cancer

Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)
Status: Recruiting Condition: Pancreatic Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Endocrine Gland Neoplasms; Pancreatic Diseases; Digestive System Diseases; Endocrine System Diseases; Gemcitabine; Antimetabolites, Antineoplastic

Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer
Status: Completed Condition: Breast Cancer

LDE225 and Paclitaxel in Solid Tumors
Status: Recruiting Condition: Advanced Solid Tumor; Ovarian Cancer

M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
Status: Recruiting Condition: Metastatic Pancreatic Cancer

Albumin-bound Paclitaxel (ABI-007) for Patients With Advanced Non-Small Cell Lung Cancer
Status: Completed Condition: Non-Small Cell Lung Carcinoma

Comparison of Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) and Taxol® Pharmacokinetics in Patients With Advanced Cancer
Status: Completed Condition: Neoplasm

Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC)
Status: Active, not recruiting Condition: HEAD & NECK Cancer

Efficacy and Safety Study of ABI-007 Plus Capecitabine as First-line Chemotherapy for Advanced Gastric Cancer Patients
Status: Not yet recruiting Condition: Gastric Adenocarcinoma

A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Status: Active, not recruiting Condition: Breast Cancer

Ph I/II Nab-Paclitaxel & Carboplatin w/Concurrent Radiation Therapy for Unresectable Stg III NSCLC
Status: Terminated Condition: Lung Cancer

Abraxane and Alimta in Advanced Solid Tumors
Status: Completed Condition: Breast Cancer; Lung Cancer; Unspecified Adult Solid Tumor, Protocol Specific

Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel
Status: Recruiting Condition: Medical Oncology

Study of Everolimus With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma
Status: Completed Condition: Metastatic Melanoma

The Addition of Nab-paclitaxel (Abraxane) to First Line Treatment of Metastasized Oesophagogastric Carcinoma (ACTION)
Status: Recruiting Condition: Esophageal Cancer; Toxicity

A Phase I/II Study of Nab-Paclitaxel, or Paclitaxel, Plus Carboplatin With Concurrent Radiation Therapy Followed by Consolidation in Patients With Favorable Prognosis Inoperable Stage IIIA/B NSCLC
Status: Recruiting Condition: INOPERABLE STAGE IIIA/B NON-SMALL CELL LUNG CANCER

Treatment With Nab-paclitaxel in Cutaneous SCC
Status: Not yet recruiting Condition: Cutaneous Squamous Cell Carcinoma

Study of Cetuximab in Combination With Carboplatin-Paclitaxel in Non-Small Cell Lung Cancer
Status: Completed Condition: Carcinoma, Non-Small-Cell Lung

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abraxis Bioscience
ABRAXANE
paclitaxel
FOR SUSPENSION;IV (INFUSION)021660Jan 7, 2005RXYes8,853,260<disabled>Y<disabled>
Teva Pharms Usa
PACLITAXEL
paclitaxel
INJECTABLE;INJECTION075297Jan 25, 2002DISCNNo<disabled><disabled>
Abraxis Bioscience
ABRAXANE
paclitaxel
FOR SUSPENSION;IV (INFUSION)021660Jan 7, 2005RXYes8,268,348<disabled><disabled>
Abraxis Bioscience
ABRAXANE
paclitaxel
FOR SUSPENSION;IV (INFUSION)021660Jan 7, 2005RXYes8,034,375<disabled><disabled>
Abraxis Bioscience
ABRAXANE
paclitaxel
FOR SUSPENSION;IV (INFUSION)021660Jan 7, 2005RXYes<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc